Apeloa Pharmaceutical (000739.SZ) Earnings Analysis

Apeloa Pharmaceutical (000739.SZ) next reports earnings on 2026-08-20, consensus EPS 0.29 CNY. Last quarter (2026-04-20) it beat with EPS 0.22 CNY vs 0.19 CNY est (+15.8%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 26.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 000739.SZ next report earnings?

Next earnings date2026-08-20
Consensus EPS estimate0.29 CNY
Revenue estimate2.47B

000739.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-200.22 CNY0.19 CNY+15.8%Beat
2026-03-200.165 CNY0.17 CNY-2.9%Miss
2025-10-210.1195 CNY0.26 CNY-54%Miss
2025-04-170.21 CNY0.34 CNY-38.2%Miss
2025-03-100.14 CNY0.3 CNY-53.3%Miss
2024-10-170.2113 CNYn/an/an/a
2024-08-150.3288 CNYn/an/an/a

Beat rate: 1/5 (20%) over reported quarters with consensus data.

000739.SZ valuation and analyst view

Trailing P/E26.40
Trailing EPS0.79149 CNY
Price / book3.53
Dividend yield2.85%
Market cap24.14B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Apeloa Pharmaceutical (000739.SZ)'s next earnings date?

Apeloa Pharmaceutical is next scheduled to report on 2026-08-20, with a consensus EPS estimate of 0.29 CNY and revenue estimate of 2.47B.

Did 000739.SZ beat earnings last quarter?

In its 2026-04-20 report, 000739.SZ posted EPS of 0.22 CNY versus a 0.19 CNY estimate — a beat of 15.8%.

What is 000739.SZ's earnings track record?

Over the last 5 reported quarters with consensus data, 000739.SZ beat estimates 1 times (20%).

What is 000739.SZ's current P/E ratio and EPS?

000739.SZ trades at a trailing P/E of 26.40 on trailing EPS of 0.7914933156775668 CNY.

What do analysts rate 000739.SZ?

000739.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.